Selected research
Industry Research
VEGF Antibody Industry Research Report 2026
Market perspective
The global VEGF Antibody market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for VEGF Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for VEGF Antibody is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for VEGF Antibody is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of VEGF Antibody include Abcam, Abnova, Absolute Antibody, Agrisera, BioLegend, Bio-Rad, Bon Opus Biosciences, Creative Biomart and Enzo Life Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global VEGF Antibody market in terms of revenue (US$ million) and, where applicable, sales volume (Kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
VEGF Antibody Market by Company
Abcam
Abnova
Absolute Antibody
Agrisera
BioLegend
Bio-Rad
Bon Opus Biosciences
Creative Biomart
Enzo Life Sciences
ImmunoStar
LifeSpan Biosciences
MilliporeSigma
Novus Biologicals
OriGene
ProMab
R&D Systems
Rockland Immunochemicals
Santa Cruz Biotechnology
Sino Biological
US Biological
Boster
Thermo Fisher
VEGF Antibody Segment by Type
Rabbit
Mouse
Goat
Others
VEGF Antibody Segment by Application
Laboratory
Hospital
Others
VEGF Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VEGF Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of VEGF Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VEGF Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of VEGF Antibody manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of VEGF Antibody by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of VEGF Antibody in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Rabbit
- Mouse
- Goat
- Others
Applications
- Laboratory
- Hospital
- Others
Companies covered
- Abcam
- Abnova
- Absolute Antibody
- Agrisera
- BioLegend
- Bio-Rad
- Bon Opus Biosciences
- Creative Biomart
- Enzo Life Sciences
- ImmunoStar
- LifeSpan Biosciences
- MilliporeSigma
- Novus Biologicals
- OriGene
- ProMab
- R&D Systems
- Rockland Immunochemicals
- Santa Cruz Biotechnology
- Sino Biological
- US Biological
- Boster
- Thermo Fisher
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global VEGF Antibody Market Size (2021-2032)
- 2.2.2 Global VEGF Antibody Sales (2021-2032)
- 2.2.3 Global VEGF Antibody Market Average Price (2021-2032)
- 2.3 VEGF Antibody by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Rabbit
- 2.3.3 Mouse
- 2.3.4 Goat
- 2.3.5 Others
- 2.4 VEGF Antibody by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Laboratory
- 2.4.3 Hospital
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global VEGF Antibody Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global VEGF Antibody Sales (Kg) of Manufacturers (2021-2026)
- 3.3 Global VEGF Antibody Revenue of Manufacturers (2021-2026)
- 3.4 Global VEGF Antibody Average Price by Manufacturers (2021-2026)
- 3.5 Global VEGF Antibody Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of VEGF Antibody, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of VEGF Antibody, Product Type & Application
- 3.8 Global Manufacturers of VEGF Antibody, Established Date
- 3.9 Global VEGF Antibody Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Abcam
- 4.1.1 Abcam Company Information
- 4.1.2 Abcam Business Overview
- 4.1.3 Abcam VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Abcam VEGF Antibody Product Portfolio
- 4.1.5 Abcam Recent Developments
- 4.2 Abnova
- 4.2.1 Abnova Company Information
- 4.2.2 Abnova Business Overview
- 4.2.3 Abnova VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Abnova VEGF Antibody Product Portfolio
- 4.2.5 Abnova Recent Developments
- 4.3 Absolute Antibody
- 4.3.1 Absolute Antibody Company Information
- 4.3.2 Absolute Antibody Business Overview
- 4.3.3 Absolute Antibody VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Absolute Antibody VEGF Antibody Product Portfolio
- 4.3.5 Absolute Antibody Recent Developments
- 4.4 Agrisera
- 4.4.1 Agrisera Company Information
- 4.4.2 Agrisera Business Overview
- 4.4.3 Agrisera VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Agrisera VEGF Antibody Product Portfolio
- 4.4.5 Agrisera Recent Developments
- 4.5 BioLegend
- 4.5.1 BioLegend Company Information
- 4.5.2 BioLegend Business Overview
- 4.5.3 BioLegend VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 BioLegend VEGF Antibody Product Portfolio
- 4.5.5 BioLegend Recent Developments
- 4.6 Bio-Rad
- 4.6.1 Bio-Rad Company Information
- 4.6.2 Bio-Rad Business Overview
- 4.6.3 Bio-Rad VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bio-Rad VEGF Antibody Product Portfolio
- 4.6.5 Bio-Rad Recent Developments
- 4.7 Bon Opus Biosciences
- 4.7.1 Bon Opus Biosciences Company Information
- 4.7.2 Bon Opus Biosciences Business Overview
- 4.7.3 Bon Opus Biosciences VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Bon Opus Biosciences VEGF Antibody Product Portfolio
- 4.7.5 Bon Opus Biosciences Recent Developments
- 4.8 Creative Biomart
- 4.8.1 Creative Biomart Company Information
- 4.8.2 Creative Biomart Business Overview
- 4.8.3 Creative Biomart VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Creative Biomart VEGF Antibody Product Portfolio
- 4.8.5 Creative Biomart Recent Developments
- 4.9 Enzo Life Sciences
- 4.9.1 Enzo Life Sciences Company Information
- 4.9.2 Enzo Life Sciences Business Overview
- 4.9.3 Enzo Life Sciences VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Enzo Life Sciences VEGF Antibody Product Portfolio
- 4.9.5 Enzo Life Sciences Recent Developments
- 4.10 ImmunoStar
- 4.10.1 ImmunoStar Company Information
- 4.10.2 ImmunoStar Business Overview
- 4.10.3 ImmunoStar VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 ImmunoStar VEGF Antibody Product Portfolio
- 4.10.5 ImmunoStar Recent Developments
- 4.11 LifeSpan Biosciences
- 4.11.1 LifeSpan Biosciences Company Information
- 4.11.2 LifeSpan Biosciences Business Overview
- 4.11.3 LifeSpan Biosciences VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 LifeSpan Biosciences VEGF Antibody Product Portfolio
- 4.11.5 LifeSpan Biosciences Recent Developments
- 4.12 MilliporeSigma
- 4.12.1 MilliporeSigma Company Information
- 4.12.2 MilliporeSigma Business Overview
- 4.12.3 MilliporeSigma VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 MilliporeSigma VEGF Antibody Product Portfolio
- 4.12.5 MilliporeSigma Recent Developments
- 4.13 Novus Biologicals
- 4.13.1 Novus Biologicals Company Information
- 4.13.2 Novus Biologicals Business Overview
- 4.13.3 Novus Biologicals VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Novus Biologicals VEGF Antibody Product Portfolio
- 4.13.5 Novus Biologicals Recent Developments
- 4.14 OriGene
- 4.14.1 OriGene Company Information
- 4.14.2 OriGene Business Overview
- 4.14.3 OriGene VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 OriGene VEGF Antibody Product Portfolio
- 4.14.5 OriGene Recent Developments
- 4.15 ProMab
- 4.15.1 ProMab Company Information
- 4.15.2 ProMab Business Overview
- 4.15.3 ProMab VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 ProMab VEGF Antibody Product Portfolio
- 4.15.5 ProMab Recent Developments
- 4.16 R&D Systems
- 4.16.1 R&D Systems Company Information
- 4.16.2 R&D Systems Business Overview
- 4.16.3 R&D Systems VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 R&D Systems VEGF Antibody Product Portfolio
- 4.16.5 R&D Systems Recent Developments
- 4.17 Rockland Immunochemicals
- 4.17.1 Rockland Immunochemicals Company Information
- 4.17.2 Rockland Immunochemicals Business Overview
- 4.17.3 Rockland Immunochemicals VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Rockland Immunochemicals VEGF Antibody Product Portfolio
- 4.17.5 Rockland Immunochemicals Recent Developments
- 4.18 Santa Cruz Biotechnology
- 4.18.1 Santa Cruz Biotechnology Company Information
- 4.18.2 Santa Cruz Biotechnology Business Overview
- 4.18.3 Santa Cruz Biotechnology VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Santa Cruz Biotechnology VEGF Antibody Product Portfolio
- 4.18.5 Santa Cruz Biotechnology Recent Developments
- 4.19 Sino Biological
- 4.19.1 Sino Biological Company Information
- 4.19.2 Sino Biological Business Overview
- 4.19.3 Sino Biological VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Sino Biological VEGF Antibody Product Portfolio
- 4.19.5 Sino Biological Recent Developments
- 4.20 US Biological
- 4.20.1 US Biological Company Information
- 4.20.2 US Biological Business Overview
- 4.20.3 US Biological VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.20.4 US Biological VEGF Antibody Product Portfolio
- 4.20.5 US Biological Recent Developments
- 4.21 Boster
- 4.21.1 Boster Company Information
- 4.21.2 Boster Business Overview
- 4.21.3 Boster VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.21.4 Boster VEGF Antibody Product Portfolio
- 4.21.5 Boster Recent Developments
- 4.22 Thermo Fisher
- 4.22.1 Thermo Fisher Company Information
- 4.22.2 Thermo Fisher Business Overview
- 4.22.3 Thermo Fisher VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.22.4 Thermo Fisher VEGF Antibody Product Portfolio
- 4.22.5 Thermo Fisher Recent Developments
5 Global VEGF Antibody Market Scenario by Region
- 5.1 Global VEGF Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global VEGF Antibody Sales by Region: 2021-2032
- 5.2.1 Global VEGF Antibody Sales by Region: 2021-2026
- 5.2.2 Global VEGF Antibody Sales by Region: 2027-2032
- 5.3 Global VEGF Antibody Revenue by Region: 2021-2032
- 5.3.1 Global VEGF Antibody Revenue by Region: 2021-2026
- 5.3.2 Global VEGF Antibody Revenue by Region: 2027-2032
- 5.4 North America VEGF Antibody Market Facts & Figures by Country
- 5.4.1 North America VEGF Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America VEGF Antibody Sales by Country (2021-2032)
- 5.4.3 North America VEGF Antibody Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe VEGF Antibody Market Facts & Figures by Country
- 5.5.1 Europe VEGF Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe VEGF Antibody Sales by Country (2021-2032)
- 5.5.3 Europe VEGF Antibody Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific VEGF Antibody Market Facts & Figures by Country
- 5.6.1 Asia Pacific VEGF Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific VEGF Antibody Sales by Country (2021-2032)
- 5.6.3 Asia Pacific VEGF Antibody Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America VEGF Antibody Market Facts & Figures by Country
- 5.7.1 South America VEGF Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America VEGF Antibody Sales by Country (2021-2032)
- 5.7.3 South America VEGF Antibody Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa VEGF Antibody Market Facts & Figures by Country
- 5.8.1 Middle East and Africa VEGF Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa VEGF Antibody Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa VEGF Antibody Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global VEGF Antibody Sales by Type (2021-2032)
- 6.1.1 Global VEGF Antibody Sales by Type (2021-2032) & (Kg)
- 6.1.2 Global VEGF Antibody Sales Market Share by Type (2021-2032)
- 6.2 Global VEGF Antibody Revenue by Type (2021-2032)
- 6.2.1 Global VEGF Antibody Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global VEGF Antibody Revenue Market Share by Type (2021-2032)
- 6.3 Global VEGF Antibody Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global VEGF Antibody Sales by Application (2021-2032)
- 7.1.1 Global VEGF Antibody Sales by Application (2021-2032) & (Kg)
- 7.1.2 Global VEGF Antibody Sales Market Share by Application (2021-2032)
- 7.2 Global VEGF Antibody Revenue by Application (2021-2032)
- 7.2.1 Global VEGF Antibody Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global VEGF Antibody Revenue Market Share by Application (2021-2032)
- 7.3 Global VEGF Antibody Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 VEGF Antibody Value Chain Analysis
- 8.1.1 VEGF Antibody Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 VEGF Antibody Production Mode & Process
- 8.2 VEGF Antibody Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 VEGF Antibody Distributors
- 8.2.3 VEGF Antibody Customers
9 Global VEGF Antibody Analyzing Market Dynamics
- 9.1 VEGF Antibody Industry Trends
- 9.2 VEGF Antibody Industry Drivers
- 9.3 VEGF Antibody Industry Opportunities and Challenges
- 9.4 VEGF Antibody Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst